Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS

被引:13
作者
Sun, Wei [1 ,2 ]
Jiang, Zhe-li [3 ]
Zhou, Lei [1 ,2 ]
Chen, Rui-min [1 ,2 ]
Wang, Zhe [1 ,2 ]
Li, Wan-shu [4 ]
Jiang, Shuo-min [1 ,2 ]
Hu, Guo-xin [3 ]
Chen, Rui-jie [1 ,2 ]
机构
[1] Second Affiliated Hosp, Wenzhou 325027, Peoples R China
[2] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Peoples R China
[3] Wenzhou Med Univ, Sch Pharm, Wenzhou 325035, Peoples R China
[4] Ningbo Municipal Hosp TCM, Ningbo 315010, Zhejiang, Peoples R China
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2015年 / 981卷
关键词
Pirfenidone; UPLC-MS/MS; Rat plasma; Pharmacokinetics; IDIOPATHIC PULMONARY-FIBROSIS; PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; METABOLITE;
D O I
10.1016/j.jchromb.2014.12.027
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A rapid, sensitive and selective ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of pirfenidone in rat plasma. Sample preparation was accomplished through a simple one-step deproteinization procedure with 0.2 mL of acetonitrile to a 0.1 mL plasma sample. Plasma samples were separated by UPLC on an Acquity UPLC BEH C18 column using a mobile phase consisting of acetonitrile-0.1% formic acid in water with gradient elution. The total run time was 3.0 min and the elution of pirfenidone was at 1.39 min. The detection was performed on a triple quadrupole tandem mass spectrometer in the multiple reaction-monitoring (MRM) mode using the respective transitions m/z 186.2 -> 92.1 for pirfenidone and m/z 237.1 -> 194.2 for carbamazepine (IS), respectively. The calibration curve was linear over the range of 5-2000 ng/mL with a lower limit of quantitation (LLOQ) of 5 ng/mL. Mean recovery of pirfenidone in plasma was in the range of 80.4-84.3%. Intra-day and inter-day precision were both <12.1%. This method was successfully applied in pharmacokinetic study after oral administration of 10.0 mg/kg pirfenidone in rats. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:14 / 18
页数:5
相关论文
共 24 条
[1]   Pharmacokinetics and metabolism of intravenous pirfenidone in sheep [J].
Bruss, Michael L. ;
Stanley, Scott D. ;
Margolin, Solomon B. ;
Giri, Shri N. .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2008, 29 (02) :119-126
[2]   Pirfenidone treatment of idiopathic pulmonary fibrosis [J].
Gan, Ye ;
Herzog, Erica L. ;
Gomer, Richard H. .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 :39-47
[3]   Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats [J].
Giri, SN ;
Al-Bayati, MA ;
Schelegle, E ;
Mohr, FC ;
Margolin, SB .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (02) :141-150
[4]   Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis [J].
Hilberg, Ole ;
Simonsen, Ulf ;
du Bois, Roland ;
Bendstrup, Elisabeth .
CLINICAL RESPIRATORY JOURNAL, 2012, 6 (03) :131-143
[5]  
Huang N-Y, 2013, Drug Res (Stuttg), V63, P388, DOI 10.1055/s-0033-1341478
[6]   Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation [J].
Iyer, SN ;
Hyde, DM ;
Giri, SN .
INFLAMMATION, 2000, 24 (05) :477-491
[7]   Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice [J].
Kehrer, JP ;
Margolin, SB .
TOXICOLOGY LETTERS, 1997, 90 (2-3) :125-132
[8]   A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis [J].
King, Talmadge E., Jr. ;
Bradford, Williamson Z. ;
Castro-Bernardini, Socorro ;
Fagan, Elizabeth A. ;
Glaspole, Ian ;
Glassberg, Marilyn K. ;
Gorina, Eduard ;
Hopkins, Peter M. ;
Kardatzke, David ;
Lancaster, Lisa ;
Lederer, David J. ;
Nathan, Steven D. ;
Pereira, Carlos A. ;
Sahn, Steven A. ;
Sussman, Robert ;
Swigris, Jeffrey J. ;
Noble, Paul W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2083-2092
[9]   Pirfenidone: an update on clinical trial data and insights from everyday practice [J].
Kreuter, Michael .
EUROPEAN RESPIRATORY REVIEW, 2014, 23 (131) :111-117
[10]   Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis [J].
Ley, Brett ;
Collard, Harold R. ;
King, Talmadge E., Jr. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (04) :431-440